RTI-51

RTI-51 (also known as 2β-propanoyl-3β-(4-tolyl)-tropane or PTT) is a synthetic compound of the phenyltropane class. It is a stimulant drug with psychostimulant properties, primarily functioning as a dopamine reuptake inhibitor. RTI-51 is part of the larger RTI series of phenyltropanes, which were developed primarily for their potential use in medical imaging.

Chemistry

RTI-51 is a phenyltropane based compound. Phenyltropanes are a family of drugs that have a tropane core structure, which is a bicyclic structure, consisting of a six-membered ring fused to a five-membered nitrogen-containing ring. The phenyltropane structure of RTI-51 is substituted at the 2β and 3β positions, with a propanoyl group at the 2β position and a 4-tolyl group at the 3β position.

Pharmacology

As a dopamine reuptake inhibitor, RTI-51 primarily acts by blocking the dopamine transporter (DAT). This leads to an increase in extracellular concentrations of dopamine, resulting in increased dopaminergic neurotransmission. This mechanism of action is similar to other psychostimulant drugs, such as cocaine and amphetamine.

Potential Medical Applications

The RTI series, including RTI-51, were initially developed for their potential use in medical imaging of the brain. Specifically, these compounds could be used in Positron Emission Tomography (PET) scans to image the distribution and density of DAT in the brain. This could potentially be useful in the diagnosis and treatment of conditions associated with altered dopaminergic neurotransmission, such as Parkinson's disease and schizophrenia.

See Also

• RTI series
• Dopamine reuptake inhibitor
• Phenyltropane